[Survival of HIV women and HAART therapy]. / Supervivencia de las mujeres infectadas por el VIH tras la aparición del TARGA.

OBJECTIVES: To assess antiretroviral treatment in women with HIV infection, to evaluate the evolution of the disease and to establish the survival rate of these patients. DESIGN: A retrospective study performed from 1985 to December, 2004. Seventy-five women, chosen randomly from all patients attending the Out-patients Department, Arnau de Vilanova Hospital, Spain. All patients were over 18 years of age, with HIV infection and undergoing antiretroviral treatment. Patients were divided into two groups according to the starting date of therapy, before or after the year 1997 when a significant change in antiretroviral therapy took place, referring both to the number of drugs used and their potency. METHODS: A comparison was made regarding the epidemiological and demographic profile, the initial and final treatment, the efficacy of antiretroviral treatment, the evolution of the HIV infection and the survival rate between both groups of patients. RESULTS: Sixty-six point seven per cent (66.7%) of the patients in the first group and 85.2% of patients in the second had negative viral loads at study end. Forty-seven point nine per cent (47.9%) of patients starting treatment before 1997, maintained CD4 lymphocyte counts above 500 cells/mL compared with 59.3% of the patients who started treatment after 1997. There were only 6 deaths, which corresponded to the first group of patients. CONCLUSIONS: The data obtained from our study suggests that antiretroviral treatment is effective in both groups of patients, and has enabled good evolution and lengthened the survival rate.

[Interruption to treatment with combined lopinavir/ritonavir therapy in HIV positive patients]. / Interrupción del tratamiento con la terapia combinada lopinavir/ritonavir en pacientes VIH+.

OBJECTIVE: To describe the extent of interruptions to treatment with therapies which include the combination of lopinavir-ritonavir within the SNS (Spanish National Health System), as well as identify the causes of these interruptions and analyse the factors associated with the same. METHOD: Retrospective cohort of 197 seropositive patients, who began treatment with lopinavir-ritonavir between January 2000 and October 2002. The patients attended the outpatient pharmaceutical care unit and were followed-up until December 2002. Interruptions and their causes were identified and the factors associated with the interruption were analysed using proportional hazard models. RESULTS: The mean follow-up period was 263 days and 38.6% of patients interrupted therapy. The most common causes of interruption were intolerance (30.3%), non-compliance (21.1%) and therapy failure (5.26%). The mean treatment period was 487 days (95% CI: 432 to 542) and 50% of patients who interrupted treatment did so within the first 4 months. No associations were found between patient or treatment characteristics and the risk of interruption. CONCLUSIONS: The percentage of interruptions was lower than those in other observational studies, but greater than those in clinical trials. The significance of the causes of interruption was similar and no factor associated with the risk of interruption was found.

Supervivencia de las mujeres infectadas por el VIH tras la aparición del TARGA / Survival of HIV women and HAART therapy

Objetivo: Valorar la eficacia del tratamiento antirretroviral en mujeres con infección por VIH, evaluar la evolución de la enfermedad y establecer la supervivencia. Diseño: Estudio retrospectivo que comprende desde el año 1985 hasta Diciembre de 2004. Incluye 75 mujeres elegidas aleatoriamente de entre todas las pacientes del Servicio de Consultas Externas del Hospital Arnau de Vilanova, mayores de 18 años, con infección por VIH y con tratamiento antirretroviral. Las pacientes se han dividido en dos grupos en función de la fecha de inicio de la terapia, antes o después de 1997, ya que a partir de este año se produjo un cambio significativo en la terapia antirretroviral. Método: Se realizó una comparación del perfil epidemiológico y demográfico, del tratamiento inicial y final, de la eficacia del tratamiento antirretroviral, de la evolución de la infección y de la supervivencia en los dos grupos de pacientes. Resultados: Un 66.7% de las pacientes del primer grupo y un 85.2% de las pacientes del segundo tuvieron cargas virales negativas al final del estudio. El 47,9% de las pacientes que iniciaron tratamiento antes de 1997 consiguieron mantener recuentos de linfocitos CD4 superior a 500 células/ml frente al 59,3% de las pacientes que iniciaron tratamiento a partir de 1997. Sólo hubo 6 fallecidos correspondiendo al primer grupo de las pacientes. Conclusiones: los datos obtenidos en nuestro estudio sugieren que el tratamiento antirretroviral ha sido eficaz en los dos grupos de pacientes lo que ha permitido una buena evolución de las mismas y prolongar su supervivencia

Objectives: To assess antiretroviral treatment in women with HIV infection, to evaluate the evolution of the disease and to establish the survival rate of these patients. Design: A retrospective study performed from 1985 to December, 2004. Seventy-five women, chosen randomly from all patients attending the Out-patients Department, Arnau de Vilanova Hospital, Spain. All patients were over 18 years of age, with HIV infection and undergoing antiretroviral treatment. Patients were divided into two groups according to the starting date of therapy, before or after the year 1997 when a significant change in antiretroviral therapy took place, referring both to the number of drugs used and their potency. Methods: A comparison was made regarding the epidemiological and demographic profile, the initial and final treatment, the efficacy of antiretroviral treatment, the evolution of the HIV infection and the survival rate between both groups of patients. Results: Sixty-six point seven per cent (66.7%) of the patients in the first group and 85.2% of patients in the second had negative viral loads at study end. Forty-seven point nine per cent (47.9%) of patients starting treatment before 1997, maintained CD4 lymphocyte counts above 500 cells/mL compared with 59.3% of the patients who started treatment after 1997. There were only 6 deaths, which corresponded to the first group of patients. Conclusions: The data obtained from our study suggests that antiretroviral treatment is effective in both groups of patients, and has enabled good evolution and lengthened the survival rate

Conciliación de la medicación al ingreso y al alta hospitalaria en un servicio de cirugía ortopédica y traumatología / Medication reconciliation at hospital admission and discharge in an orthopedic surgery and traumatology department

Objetivo: Evaluar los resultados de un programa de conciliación e información de medicación al alta hospitalaria en un servicio de cirugía ortopédica y traumatología. Material y método: Se incluyeron los pacientes ingresados durante 2008 con mayor complejidad en su tratamiento domiciliario. Este se registró y se confirmó, mediante una entrevista con el paciente, la adherencia a éste, así como problemas relacionados con la medicación (PRM). A partir de la epicrisis, se concilió la medicación prescrita con el tratamiento ambulatorio y se resolvieron las discrepancias con el facultativo encargado. Por último, se entregó al paciente el listado completo de su medicación a partir del episodio asistencial y recomendaciones sobre su tratamiento, con la explicación verbal de este. Realizamos una encuesta de satisfacción a los traumatólogos para conocer el conocimiento del programa y su valoración. Resultados: Se seleccionaron 243 pacientes; en 102 (42%) se detectaron PRM. Las principales discrepancias se encontraron en fármacos antitrombóticos (25%) y analgésicos y antiinflamatorios (21%). Las discrepancias más frecuentes fueron la duplicidad terapéutica (53%) y las interacciones (27%). Los PRM se clasificaron según su gravedad: el 65% no habría causado daño al paciente y un 35% requeriría monitorización. Resultados: En cuanto a la encuesta de satisfacción, la valoración global del programa fue «muy buena» para el 100% de los facultativos. Discusión: La conciliación de medicación se ha mostrado como una estrategia útil para aumentar la seguridad de nuestros pacientes, en el marco de un sistema de reducción de riesgos para la salud y mejora de la calidad asistencial (AU)

Purpose: To evaluate the results of a medication reconciliation and drug information program at discharge in an orthopedic surgery and traumatology department. Materials and methods: Patients with more complexity in their home treatment, admitted in this facility during 2008 were included in the study. Preadmission regimens were recorded and the patents were asked about medication-related problems (PRM) and drug adherence. On the day of discharge, prescribed medication was reconciled with the outpatient treatment, resolving discrepancies with the prescribers. Finally, the patients were given a complete list of their medications after the care episode and recommendations on their treatment with oral explanation. We conducted a survey of the physicians to ask about their reconciliation program knowledge and their assessment.Results243 patients were selected, in whom 102 (42%) PRMs were detected. The major discrepancies were found in antithrombotic drugs (25%) and analgesics and anti-inflammatory drugs (21%). The most frequent were: therapeutic duplication (53%) and interactions (27%). The PRMs were classified according to their severity: 65% would not have caused harm to the patient and 35% would require monitoring. Results: Regarding the survey, the overall evaluation of the program was "very good" for 100% of the physicians. Discussion: Medication reconciliation has proved to be a useful strategy for improving the safety of our patients as part of a system to reduce health risks and improving quality of care (AU)

Interrupción del tratamiento con la terapia combinada lopinavir/ritonavir en pacientes VIH+ / No disponible

Objetivo: Describir, en el entorno del Sistema Nacional deSalud (SNS), la magnitud de la interrupción del tratamiento conterapias que incluyen la combinación lopinavir/ritonavir, identificarlas causas de estas interrupciones y analizar los factores asociadosa las mismas.Método: Cohorte retrospectiva de 197 pacientes seropositivosque iniciaron tratamiento con lopinavir/ritonavir entre enerode 2000 y octubre de 2002 en la unidad de atención farmacéuticaa pacientes externos, y fueron seguidos hasta diciembre de 2002.Se identificaron los casos de interrupción y sus causas y se analizaron,utilizando modelos de riesgos proporcionales, los factoresasociados a la interrupción.Resultados: La duración media de seguimiento fue de 263días. El 38,6% de los pacientes interrumpió el tratamiento, siendolas causas más frecuentes la intolerancia (30,3%), el incumplimiento(21,1%) y el fracaso terapéutico (5,26%). La mediana deduración del tratamiento fue de 487 días (IC95%: 432-542) y el50% de los casos que interrumpieron lo hicieron antes de4 meses. No se hallaron asociaciones entre características de lospacientes o del tratamiento y el riesgo de interrupción.Conclusiones: El porcentaje de interrupciones fue inferior alde otros estudios observacionales pero superior al de los ensayosclínicos. La importancia de las causas de interrupción fue similar.No se halló ningún factor asociado al riesgo de interrupción

Objective: To describe the extent of interruptions to treatmentwith therapies which include the combination of lopinavirritonavirwithin the SNS (Spanish National Health System), as wellas identify the causes of these interruptions and analyse the factorsassociated with the same.Method: Retrospective cohort of 197 seropositive patients,who began treatment with lopinavir-ritonavir between January2000 and October 2002. The patients attended the outpatientpharmaceutical care unit and were followed-up until December2002. Interruptions and their causes were identified and the factorsassociated with the interruption were analysed using proportionalhazard models.Results: The mean follow-up period was 263 days and38.6% of patients interrupted therapy. The most common causesof interruption were intolerance (30.3%), non-compliance(21.1%) and therapy failure (5.26%). The mean treatment periodwas 487 days (95% CI: 432 to 542) and 50% of patients whointerrupted treatment did so within the first 4 months. No associationswere found between patient or treatment characteristics andthe risk of interruption.Conclusions: The percentage of interruptions was lower thanthose in other observational studies, but greater than those in clinicaltrials. The significance of the causes of interruption was similarand no factor associated with the risk of interruption wasfound